The estimated Net Worth of Robb Knie is at least $594 millier dollars as of 16 August 2024. Mr Knie owns over 25,000 units of Hoth Therapeutics stock worth over $69,176 and over the last 5 years he sold HOTH stock worth over $0. In addition, he makes $525,000 as Pres et CEO & Chairman at Hoth Therapeutics.
Mr has made over 3 trades of the Hoth Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of HOTH stock worth $16,750 on 16 August 2024.
The largest trade he's ever made was buying 25,000 units of Hoth Therapeutics stock on 16 August 2024 worth over $16,750. On average, Mr trades about 4,500 units every 70 days since 2019. As of 16 August 2024 he still owns at least 58,131 units of Hoth Therapeutics stock.
You can see the complete history of Mr Knie stock trades at the bottom of the page.
Robb Knie is the Pres, CEO & Chairman at Hoth Therapeutics.
As the Pres et CEO & Chairman of Hoth Therapeutics, the total compensation of Mr Knie at Hoth Therapeutics is $525,000. There are no executives at Hoth Therapeutics getting paid more.
Mr Knie is 52, he's been the Pres et CEO & Chairman of Hoth Therapeutics since . There are no older and 3 younger executives at Hoth Therapeutics.
Robb's mailing address filed with the SEC is C/O HOTH THERAPEUTICS, INC., 590 MADISON AVENUE, 21ST FLOOR, NEW YORK, NY, 10022.
Over the last 6 years, insiders at Hoth Therapeutics have traded over $500,000 worth of Hoth Therapeutics stock and bought 45,000 units worth $24,650 . The most active insiders traders include Anthony Hayes et Robb Knie. On average, Hoth Therapeutics executives and independent directors trade stock every 386 days with the average trade being worth of $132,388. The most recent stock trade was executed by Robb Knie on 16 August 2024, trading 25,000 units of HOTH stock currently worth $16,750.
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Hoth Therapeutics executives and other stock owners filed with the SEC include: